Waldenström Macroglobulinemia
Specialty Channel

Featured Article
Phase 2 study findings suggest obinutuzumab in combination with idelalisib is an effective treatment option for patients with relapsed/refractory WM.
True or False: In contrast to the first and second generation BTK inhibitors, the third‑generation LOXO‑305 is known to obtain non‑covalent binding and reversible qualities in patients with…
True or False: Results from a retrospective analysis suggest that both autologous and allogeneic stem cell transplantation have a potential role in the treatment of patients with Waldenström’s…
True or False: Ibrutinib does not promote long-term disease control in previously-treated Waldenstrom macroglobulinemia.
An analysis of a multi-center trial comprising patients with previously-treated WM has shown ibrutinib to have promising long-term activity in this setting.
True or False: Zanubrutinib has been associated with higher complete response and very good partial response rates in patients with WM.
True or False: The ASPEN trial was the first trial to compare BTK inhibitors head-to-head in any disease.
True or False: Ibrutinib may prevent lung injury and improve pulmonary function in hypoxic patients with WM who have COVID-19.
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.

News

Phase 2 study findings suggest obinutuzumab in combination with idelalisib is an effective treatment option for patients with relapsed/refractory WM.
An analysis of a multi-center trial comprising patients with previously-treated WM has shown ibrutinib to have promising long-term activity in this setting.
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.
Zanubrutinib appears to be associated with a higher CR and VGPR rate and demonstrates clinically meaningful advantages in safety and tolerability compared to ibrutinib for WM.

Interactive Features

True or False: In contrast to the first and second generation BTK inhibitors, the third‑generation LOXO‑305 is known to obtain non‑covalent binding and reversible qualities in patients with…
True or False: Results from a retrospective analysis suggest that both autologous and allogeneic stem cell transplantation have a potential role in the treatment of patients with Waldenström’s…
True or False: Ibrutinib does not promote long-term disease control in previously-treated Waldenstrom macroglobulinemia.
True or False: Zanubrutinib has been associated with higher complete response and very good partial response rates in patients with WM.
Stay in the know.
OncNet Newsletter